Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence
June 3, 2025
Patients with cutaneous squamous cell carcinoma treated with cemiplimab (brand name LIBTAYO) had longer disease-free survival than patients treated with…















